dupilumab治疗严重哮喘7天内的早期应答者通过患者报告的结果评估:一项试点研究

IF 2.3 Multidisciplinary Respiratory Medicine Pub Date : 2021-03-17 eCollection Date: 2021-01-15 DOI:10.4081/mrm.2021.736
Nozomi Tani, Nobutaka Kataoka, Yusuke Kunimatsu, Yusuke Tachibana, Takumi Sugimoto, Izumi Sato, Yuri Ogura, Kazuki Hirose, Takayuki Takeda
{"title":"dupilumab治疗严重哮喘7天内的早期应答者通过患者报告的结果评估:一项试点研究","authors":"Nozomi Tani,&nbsp;Nobutaka Kataoka,&nbsp;Yusuke Kunimatsu,&nbsp;Yusuke Tachibana,&nbsp;Takumi Sugimoto,&nbsp;Izumi Sato,&nbsp;Yuri Ogura,&nbsp;Kazuki Hirose,&nbsp;Takayuki Takeda","doi":"10.4081/mrm.2021.736","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and innate immunity pathways through fast signal transduction, leading to an early response to treatment. Although rapid improvement within 1-3 days after dupilumab treatment was observed in moderate-to-severe atopic dermatitis, an early response within 7 days of dupilumab treatment in severe asthma has not been reported.</p><p><strong>Methods: </strong>Twelve consecutive patients with severe asthma who were newly treated with dupilumab between July 2019 and April 2020 were retrospectively investigated. We evaluated the early response (within 7 days) of patients with severe asthma receiving dupilumab therapy. Asthma control test (ACT) and the daily ACT, which was modified from the ACT to evaluate daily symptoms associated with asthma, were adopted as patient-reported outcomes (PROs) at week 8 and within 7 days, respectively. Patients were stratified into early responders (7 days), late responders (week 8), and non-responders without significant improvement in PROs. Descriptive statistics were adopted due to the limited number of patients.</p><p><strong>Results: </strong>Four of these 12 patients were early responders, with the following baseline characteristics: body mass index, <25 kg/m<sup>2</sup>; without depression; baseline forced expiratory volume in 1 second, <1.50 L; and more than one exacerbation in 1 year. On the other hand, five were late responders, and 44.4% of the nine responders were early responders. The higher the eosinophilic count and/or FeNO did not show any relationship between the early responder and nonresponder.</p><p><strong>Conclusions: </strong>The effect of dupilumab on severe asthma in patients with atopic features could be started earlier than 2 weeks, similar to atopic dermatitis. Daily ACT may be useful in monitoring the early efficacy of dupilumab in treating severe asthma.</p>","PeriodicalId":49031,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/fd/mrm-16-1-736.PMC7993019.pdf","citationCount":"2","resultStr":"{\"title\":\"Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.\",\"authors\":\"Nozomi Tani,&nbsp;Nobutaka Kataoka,&nbsp;Yusuke Kunimatsu,&nbsp;Yusuke Tachibana,&nbsp;Takumi Sugimoto,&nbsp;Izumi Sato,&nbsp;Yuri Ogura,&nbsp;Kazuki Hirose,&nbsp;Takayuki Takeda\",\"doi\":\"10.4081/mrm.2021.736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and innate immunity pathways through fast signal transduction, leading to an early response to treatment. Although rapid improvement within 1-3 days after dupilumab treatment was observed in moderate-to-severe atopic dermatitis, an early response within 7 days of dupilumab treatment in severe asthma has not been reported.</p><p><strong>Methods: </strong>Twelve consecutive patients with severe asthma who were newly treated with dupilumab between July 2019 and April 2020 were retrospectively investigated. We evaluated the early response (within 7 days) of patients with severe asthma receiving dupilumab therapy. Asthma control test (ACT) and the daily ACT, which was modified from the ACT to evaluate daily symptoms associated with asthma, were adopted as patient-reported outcomes (PROs) at week 8 and within 7 days, respectively. Patients were stratified into early responders (7 days), late responders (week 8), and non-responders without significant improvement in PROs. Descriptive statistics were adopted due to the limited number of patients.</p><p><strong>Results: </strong>Four of these 12 patients were early responders, with the following baseline characteristics: body mass index, <25 kg/m<sup>2</sup>; without depression; baseline forced expiratory volume in 1 second, <1.50 L; and more than one exacerbation in 1 year. On the other hand, five were late responders, and 44.4% of the nine responders were early responders. The higher the eosinophilic count and/or FeNO did not show any relationship between the early responder and nonresponder.</p><p><strong>Conclusions: </strong>The effect of dupilumab on severe asthma in patients with atopic features could be started earlier than 2 weeks, similar to atopic dermatitis. Daily ACT may be useful in monitoring the early efficacy of dupilumab in treating severe asthma.</p>\",\"PeriodicalId\":49031,\"journal\":{\"name\":\"Multidisciplinary Respiratory Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2021-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/fd/mrm-16-1-736.PMC7993019.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multidisciplinary Respiratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/mrm.2021.736\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/15 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multidisciplinary Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/mrm.2021.736","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/15 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

背景:严重哮喘相关症状的处理是必要的,因为这些症状对受影响的患者来说是痛苦的,并且也极大地影响了他们的生活质量。Dupilumab是一种单克隆抗体,可阻断白细胞介素(IL)-4和IL-13信号传导,这两种信号通过快速信号转导在获得性和先天免疫途径中至关重要,从而导致对治疗的早期反应。虽然dupilumab治疗中重度特应性皮炎后1-3天内观察到快速改善,但dupilumab治疗严重哮喘后7天内的早期反应尚未报道。方法:回顾性分析2019年7月至2020年4月连续12例新接受杜匹单抗治疗的重症哮喘患者。我们评估了接受dupilumab治疗的严重哮喘患者的早期反应(7天内)。在第8周和第7天内,分别采用哮喘控制试验(ACT)和每日ACT作为患者报告的结果(PROs)。每日ACT由ACT改进,用于评估与哮喘相关的每日症状。患者被分为早期应答者(7天)、晚期应答者(第8周)和无应答者(无明显改善)。由于患者数量有限,采用描述性统计。结果:这12例患者中有4例是早期应答者,具有以下基线特征:体重指数,2;没有抑郁症;结论:与特应性皮炎相似,dupilumab治疗具有特应性特征的重症哮喘可早于2周开始。每日ACT可用于监测dupilumab治疗严重哮喘的早期疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Background: The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and innate immunity pathways through fast signal transduction, leading to an early response to treatment. Although rapid improvement within 1-3 days after dupilumab treatment was observed in moderate-to-severe atopic dermatitis, an early response within 7 days of dupilumab treatment in severe asthma has not been reported.

Methods: Twelve consecutive patients with severe asthma who were newly treated with dupilumab between July 2019 and April 2020 were retrospectively investigated. We evaluated the early response (within 7 days) of patients with severe asthma receiving dupilumab therapy. Asthma control test (ACT) and the daily ACT, which was modified from the ACT to evaluate daily symptoms associated with asthma, were adopted as patient-reported outcomes (PROs) at week 8 and within 7 days, respectively. Patients were stratified into early responders (7 days), late responders (week 8), and non-responders without significant improvement in PROs. Descriptive statistics were adopted due to the limited number of patients.

Results: Four of these 12 patients were early responders, with the following baseline characteristics: body mass index, <25 kg/m2; without depression; baseline forced expiratory volume in 1 second, <1.50 L; and more than one exacerbation in 1 year. On the other hand, five were late responders, and 44.4% of the nine responders were early responders. The higher the eosinophilic count and/or FeNO did not show any relationship between the early responder and nonresponder.

Conclusions: The effect of dupilumab on severe asthma in patients with atopic features could be started earlier than 2 weeks, similar to atopic dermatitis. Daily ACT may be useful in monitoring the early efficacy of dupilumab in treating severe asthma.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Multidisciplinary Respiratory Medicine
Multidisciplinary Respiratory Medicine Medicine-Pulmonary and Respiratory Medicine
自引率
0.00%
发文量
23
期刊介绍: Multidisciplinary Respiratory Medicine is the official journal of the Italian Respiratory Society - Società Italiana di Pneumologia (IRS/SIP). The journal publishes on all aspects of respiratory medicine and related fields, with a particular focus on interdisciplinary and translational research. The interdisciplinary nature of the journal provides a unique opportunity for researchers, clinicians and healthcare professionals across specialties to collaborate and exchange information. The journal provides a high visibility platform for the publication and dissemination of top quality original scientific articles, reviews and important position papers documenting clinical and experimental advances.
期刊最新文献
Characteristics of culture-negative subclinical pulmonary tuberculosis: a single-center observation. Effective treatment with oral Salbutamol on late onset respiratory impairment in a DOK7 Congenital Myasthenia Syndrome: a case report. Gas exchange abnormalities in Long COVID are driven by the alteration of the vascular component Usability of inhaler devices: a parameter currently misused Characteristics of inpatients with atopic asthma in a tertiary center: do age and gender have an influence?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1